Summit Panelist Spotlight: Dr. Steven Gray

by | Aug 29, 2016 | 0 comments

SteveGray_20150417 (2)Dr. Steven J. Gray is an Assistant Professor in the Dept. of Ophthalmology, U. of N. Carolina at Chapel Hill. He is also an investigator in the UNC Gene Therapy Center and Carolina Institute for Developmental Disabilities. Dr. Gray was previously a Post Doc at UNC and before that had undertaken a PhD in Molecular Biology, at Vanderbilt University.

His core expertise is in AAV gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system or eye. His major focus is in AAV vector development, creating vectors tailored to serve specific clinical and research applications involving the nervous system. These include the development of novel AAV capsids amenable to widespread CNS gene transfer or specialized ocular gene transfer.

As AAV-based platform gene transfer technologies have been developed to achieve global, efficient, and in some cases cell-type specific CNS gene delivery, his research focus has also included preclinical studies to apply these reagents toward the development of treatments for neurological diseases. Currently, these include preclinical studies for Rett Syndrome, Giant Axonal Neuropathy (GAN), Tay-Sachs, Krabbe, AGU, and Batten Disease, and have expanded into human clinical studies to test a gene therapy approach for GAN. He has published over 40 peer reviewed papers and has 3 pending patents. His research is funded by NIH and other research foundations.

Learn more on this topic

Related Blog Posts

CMT Kids Video

The Hereditary Neuropathy Foundation is currently seeking 10 second video clips of CMT patients under the age of 16, performing daily activities.

Summit Panelist Spotlight: Mitchell Warner

Bracing is used in the management Charcot-Marie-Tooth to support and hold a part of the body compromised by muscle weakness, muscular atrophy, sensory impairment. Bracing is also used to help correct skeletal deformity.

Summit Panelist Spotlight: Brent Baker

With respect to CMT, Dr. Baker’s team has collaborated with Drs. Michael Sereda and Klaus Nave of the Max Planck Institute for Experimental Medicine (MPI) to utilize their CMT1A transgenic rat and established the initial CMT1A rat colony in the United States.

Summit Speaker Spotlight: Dr. Timothy R. Coté

HNF has invited Dr. Coté to lead the discussion on Public Policy. We will cover issues such as better AFO (leg-bracing) options, fast-tracking drug discoveries and clinical trials, applying for disability benefits, Medicare/Medicaid and services.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news